Rolling submission would license the jab for individuals 18 and up
Moderna, who plans on revving up its vaccine supply to up to 3 billion doses by next year, has officially begun a biologics license application (BLA) with FDA for approval of its two-dose mRNA shot to prevent Covid-19 in people 18 years of age and older.
The vaccine was granted emergency use authorization (EUA) back in December 2020.
As noted by Stéphane Bancel, Moderna’s CEO, the company will continue to submit Phase III data to support the BLA on a rolling basis over the coming weeks with a request for a priority review. Once the rolling BLA submission is complete, FDA will notify Moderna of when it is formally accepted for review.
Two other manufacturers of the vaccine, Pfizer and BioNTech, initiated the rolling process last month.
An Exploration of Compounding Practices
May 22nd 2025In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also shedding light on the FDA’s impact when it comes to improving the safety, quality, and trust in compounded drugs.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.